Drug combos could be "practice changing" for advanced breast cancer

12/8/2011 | MSNBC · HealthDay News

Two experimental drug combinations extended survival in women with advanced breast cancer, according to studies presented at the San Antonio Breast Cancer Symposium and published in The New England Journal of Medicine. In one study, women with HER2-positive breast cancer treated with Genentech's Herceptin, chemotherapy and experimental drug pertuzumab lived an average of 18.5 months without recurrence, compared with 12.4 months in the group receiving only Herceptin and chemotherapy. Genentech applied for FDA approval of pertuzumab this week.

View Full Article in:

MSNBC · HealthDay News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health